OBJECTIVE: To evaluate the efficacy of intravascular intervention in the management of different types of Budd-Chiari syndrome. METHODS: Fifty-three patients of BCS were clinically diagnosed and interventionally treated in terms of their signs and symptoms of portal hypertension and occlusive inferior vena cava/or hepatic veins with the combination of Doppler ultrasonography, CT scan, and angiography. The interventional methods applied in this study included percutaneous transluminal angioplasty and IVC stent implantation (PTA+IVC stent); transjugular hepatic veno-stent placement (PTA+HV stent) or transjugular transluminal hepatic veno-inferior vena cava stent placement and transcaval transjugular intrahepatic portocaval shunt. RESULTS: The success rate of intravascular interventional therapy was 92.45% (49/53). After interventional therapy, the patients' pleural effusion, ascites, prominent veins formation of bilateral flanks or backs alleviated, hepatomegaly reduced, and the urinary output increased. The longest follow-up case was 13 years with patent stent. Two patients died of pulmonary embolization or pericardial tamponade during surgery. CONCLUSION: Intravascular intervention is a safe and effective therapy for most types of BCS.
OBJECTIVE: To evaluate the efficacy of intravascular intervention in the management of different types of Budd-Chiari syndrome. METHODS: Fifty-three patients of BCS were clinically diagnosed and interventionally treated in terms of their signs and symptoms of portal hypertension and occlusive inferior vena cava/or hepatic veins with the combination of Doppler ultrasonography, CT scan, and angiography. The interventional methods applied in this study included percutaneous transluminal angioplasty and IVC stent implantation (PTA+IVC stent); transjugular hepatic veno-stent placement (PTA+HV stent) or transjugular transluminal hepatic veno-inferior vena cava stent placement and transcaval transjugular intrahepatic portocaval shunt. RESULTS: The success rate of intravascular interventional therapy was 92.45% (49/53). After interventional therapy, the patients' pleural effusion, ascites, prominent veins formation of bilateral flanks or backs alleviated, hepatomegaly reduced, and the urinary output increased. The longest follow-up case was 13 years with patent stent. Two patients died of pulmonary embolization or pericardial tamponade during surgery. CONCLUSION: Intravascular intervention is a safe and effective therapy for most types of BCS.
Authors: J I Bilbao; J C Pueyo; J M Longo; M Arias; J I Herrero; A Benito; M D Barettino; J P Perotti; F Pardo Journal: Cardiovasc Intervent Radiol Date: 1997 Mar-Apr Impact factor: 2.740
Authors: Antonia Perelló; Juan Carlos García-Pagán; Rosa Gilabert; Yanette Suárez; Eduardo Moitinho; Francisco Cervantes; Juan Carlos Reverter; Angels Escorsell; Jaume Bosch; Juan Rodés Journal: Hepatology Date: 2002-01 Impact factor: 17.425